Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic
Hematol., Transfus. Cell Ther. (Impr.)
; 42(3): 195-199, July-Sept. 2020.
Article
em En
| LILACS
| ID: biblio-1134039
Biblioteca responsável:
BR408.1
Localização: BR408.1
ABSTRACT
ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay. This guideline aims to give providers a sense of direction in order to better take care of patients and prioritize care.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
SARS-CoV-2
/
COVID-19
/
Transtornos Mieloproliferativos
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Assunto da revista:
Hematologia
/
TransfusÆo de Sangue
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Brasil